Advertisement

Inzidenz der Faktor VIII-Hemmkörperentwicklung bei Hämophilie-Patienten und kumulatives Risiko in Abhängigkeit von Alter und Substitutionstherapie. Ergebnisse einer 15jährigen Longitudinal-Studie

  • S. Ehrenforth
  • W. Kreuz
  • R. Linde
  • D. Menzer
  • T. Beeg
  • I. Scharrer
Conference paper

Zusammenfassung

Die Entwicklung von IgG-Antikörpern gegen substituierten Faktor VIII: C, bleibt trotz der vielen neuen Erkenntnisse auf dem Gebiet ihrer molekularbiologischen Eigenschaften weiterhin ein gravierendes und bisher ungelöstes Problem der Hämophiliebehandlung.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Biggs R (1974) Jaundice and antibodies directed against factors VIII and IX in patients treated for haemophilia or Christmas disease in the United Kingdom. Br J Haematol 26:313–329PubMedCrossRefGoogle Scholar
  2. Brinkhous KM, Roberts HR, Weiss AE (1972) Prevalence of inhibitors in hemophilia A and B. Thromb Diath Haemorrh Suppl 51:315–321Google Scholar
  3. Gill FM, Shapiro SS, Poole WK.et al (1984) The natural history of factor VIII inhibitors in patients with Hemophilia A. In: Hoyer LW (ed) „Factor VIII Inhibitors. “ New York: Alan R Liss, Inc, p 19Google Scholar
  4. Ikkala E, Simonen O (1971) Factor VIII inhibitors and the use of blood products in patients with haemophilia A. Scand J Haemat 8:16–20PubMedCrossRefGoogle Scholar
  5. Kasper CK (1973) Incidence and course of inhibitors among patients with classic haemophi­lia. Thrombo Diath Haemorrh 30:263–271Google Scholar
  6. Schwartz RS, Abildgaard CF, Aledort LM et al (1990) Human recombinant DNA-derived antihemophilic factor (F VIII) in the treatment of hemophilia A. N Engl J Med 323:1799–1805Google Scholar
  7. Schwarzinger I, Pabinger I, Korninger C et al (1987) Incidence of Inhibitors in Patients with Severe and Moderate Hemophilia A Treated with Factor VIII Concentrates. American J of Hematology 24:241–245CrossRefGoogle Scholar
  8. Strauss HS (1969) Aquired circulating anticoagulants in hemophilia A. N Engl J Med 281:886–873Google Scholar
  9. Allain JP, Frommel D (1976) Antibodies to Factor VIII. V. Patterns of Immune Response to Factor VIII in Hemophilia A. Blood 47:973Google Scholar
  10. Ruggeri ZM (1977). Natural history of 39 factor VIII inhibitors in hemophilias. In: Work­shop on Inhibitors of Factors VIII and IX. Facultas-Verlag Wien, p 45–48Google Scholar
  11. Shapiro SS (1979) Antibodies to blood coagulation factors. Clinics in Haematology 8:207–214PubMedGoogle Scholar
  12. Shapiro SS, Hultin M (1975) Acquired inhibitors to the blood coagulation factors. Semin Thromb Hemost 1:336Google Scholar
  13. Langdell RD, Wagner RH, Brinkhous KM (1953) Effect of antihaemophilic factor on one-stage-clotting test: A presumptive test for haemophilia and a simple one-stage antihae­mophilic factor assay procedure. J Lab Clin Med 41:637–645Google Scholar
  14. Kasper CK, Aledort LM, Counts RB et al (1975) A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 34:869Google Scholar
  15. Kaplan EL, Meier (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481CrossRefGoogle Scholar
  16. Ikkala E, Helske T, Myllyläg G et al (1982) Changes in the life-expectancy of patients with severe haemophilia A in Finland in 1930–1979. Br J Haematol 52:7–12PubMedCrossRefGoogle Scholar
  17. Rizza CR, Spooner RJD (1983) Treatment of hemophilia and related disorders in Britain and Northern Ireland during 1976–1980: Report on behalf of the directors of hemophilia centres in the United Kingdom. Br Med J 286:929Google Scholar
  18. Larsson SA (1985) Life expectancy of Swedish haemophiliacs 1831–1980. Br J Haematol 59:593–602PubMedCrossRefGoogle Scholar
  19. Rosendaal FR, Varekamp I, Smit C et al (1989) Mortality and causes of death in Dutch hemophiliacs 1973–1986. Br J Haematol 71:71–76PubMedCrossRefGoogle Scholar
  20. Mc Millan CW, Shapiro SS, Whitehurst D et al (1988) The natural history of factor VIII inhibitors in patients with hemophilia A: A national cooperative study. II. Observations on the initial development of factor VIII: C inhibitors. N Engl J Med 71:344–348Google Scholar
  21. Rasi V, Ikkala E (1990) Haemophiliacs with factor VIII inhibitors in Finland: prevalence, incidence and outcome. Br J Haematol 76:369–371PubMedCrossRefGoogle Scholar
  22. Shapiro SS (1984) Markers for the Factor VIII Antibody Response in Hemophilia A. Scand J Haematol-Suppl 40:33, 181 –185PubMedGoogle Scholar
  23. Kesteven PJ, Holland LJ, Lawrie AS et al (1984) Inhibitor to Faktor VIII in Mild Hemophilia. Thromb Haemostas 52:50–52Google Scholar
  24. Stenbjerg S, Ingerslev J, Zachariae E (1984). Factor VIII inhibitor treatment with high doses of factor VIII. Thrombosis Research 34:533–539PubMedCrossRefGoogle Scholar
  25. 25.
    Kreuz W, Ehrenforth S, Scharrer I et al (1991) Factor VIII inhibitors in children with haemophilia. Long-term longitudinal results of dose-dependent induced immunotolerance. Annals of Hematol 62: A 46Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • S. Ehrenforth
    • 1
  • W. Kreuz
    • 1
  • R. Linde
    • 1
  • D. Menzer
    • 1
  • T. Beeg
    • 1
  • I. Scharrer
    • 1
  1. 1.Frankfurt/MainDeutschland

Personalised recommendations